InDex Pharmaceuticals gets new patent for cobitolimod granted in Canada
November 16, 2021 – InDex Pharmaceuticals Holding AB (publ) today announced that a new method of use patent for the drug candidate cobitolimod has been granted by the Canadian Intellectual Property Office (CIPO). The patent provides additional protection for the use of certain dosage regimens of cobitolimod for treating chronic active ulcerative colitis in patients that are not responding or are intolerant to anti-inflammatory therapy.The patent, entitled Method for prevention of colectomy (patent number CA2892203), will provide an exclusivity period until November 2032, with the